FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898825809> ?p ?o ?g. }

• W2898825809 endingPage "3457" @default.
• W2898825809 startingPage "3445" @default.
• W2898825809 abstract "Recently, targeted agents were reported to improve overall survival, progression-free survival (PFS), response rate, and quality of life compared with cytotoxic chemotherapies, which provides hope for the treatment of non-small-cell lung cancer (NSCLC). The network meta-analysis is applied to compare the efficacies and adverse events of five targeted agents (erlotinib, gefitinib, vandetanib, dacomitinib, and icotinib) for advanced or metastatic NSCLC. Nine eligible randomized controlled trials from PubMed and Cochrane Library database were included. Weighted mean difference, odds ratio, and surface under the cumulative ranking curve (SUCRA) values were evaluated for the efficacy and adverse events of the five targeted agents in the treatment of NSCLC. With regard to efficacy, the overall response rate (ORR) of advanced or metastatic NSCLC patients treated with gefitinib was relatively higher than those treated with placebo. Compared with patients treated with placebo, the disease control rate (DCR) of patients treated with erlotinib and with gefitinib was relatively higher. Furthermore, in terms of PFS and DCR, the SUCRA value of icotinib was the highest among the five targeted drugs. With regard to ORR, the SUCRA value of gefitinib was the highest among the five targeted drugs. In terms of fatigue, rash, and cough, erlotinib had the lowest SUCRA value, whereas vandetanib exhibited the lowest SUCRA value in terms of diarrhea. Our study suggests that the efficacies of gefitinib and icotinib for advanced or metastatic NSCLC were comparatively better, whereas the toxicities of erlotinib and vandetanib were relatively greater." @default.
• W2898825809 created "2018-11-09" @default.
• W2898825809 creator A5027339124 @default.
• W2898825809 creator A5032880409 @default.
• W2898825809 creator A5046857076 @default.
• W2898825809 creator A5048352507 @default.
• W2898825809 creator A5051862250 @default.
• W2898825809 date "2018-10-30" @default.
• W2898825809 modified "2023-09-26" @default.
• W2898825809 title "Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non‐small‐cell lung cancer: A network meta‐analysis of nine eligible randomized controlled trials involving 5,059 patients" @default.
• W2898825809 cites W1481153401 @default.
• W2898825809 cites W1516434454 @default.
• W2898825809 cites W1860321953 @default.
• W2898825809 cites W1964238015 @default.
• W2898825809 cites W1978111504 @default.
• W2898825809 cites W1993382872 @default.
• W2898825809 cites W1997069340 @default.
• W2898825809 cites W2010699829 @default.
• W2898825809 cites W2015104488 @default.
• W2898825809 cites W2018652673 @default.
• W2898825809 cites W2031699458 @default.
• W2898825809 cites W2040181388 @default.
• W2898825809 cites W2041731270 @default.
• W2898825809 cites W2053629542 @default.
• W2898825809 cites W2068815946 @default.
• W2898825809 cites W2081381356 @default.
• W2898825809 cites W2091808438 @default.
• W2898825809 cites W2094793971 @default.
• W2898825809 cites W2098923148 @default.
• W2898825809 cites W2099180737 @default.
• W2898825809 cites W2100912832 @default.
• W2898825809 cites W2100950755 @default.
• W2898825809 cites W2113491100 @default.
• W2898825809 cites W2115078104 @default.
• W2898825809 cites W2119501407 @default.
• W2898825809 cites W2124464299 @default.
• W2898825809 cites W2137145593 @default.
• W2898825809 cites W2143732277 @default.
• W2898825809 cites W2151225337 @default.
• W2898825809 cites W2152171507 @default.
• W2898825809 cites W2154734647 @default.
• W2898825809 cites W2156471067 @default.
• W2898825809 cites W2159192794 @default.
• W2898825809 cites W2160889088 @default.
• W2898825809 cites W2168431214 @default.
• W2898825809 cites W2273212719 @default.
• W2898825809 cites W2307548938 @default.
• W2898825809 cites W2499244543 @default.
• W2898825809 cites W2512471417 @default.
• W2898825809 cites W2527029271 @default.
• W2898825809 cites W4238604577 @default.
• W2898825809 doi "https://doi.org/10.1002/jcp.26793" @default.
• W2898825809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30374969" @default.
• W2898825809 hasPublicationYear "2018" @default.
• W2898825809 type Work @default.
• W2898825809 sameAs 2898825809 @default.
• W2898825809 citedByCount "1" @default.
• W2898825809 countsByYear W28988258092021 @default.
• W2898825809 crossrefType "journal-article" @default.
• W2898825809 hasAuthorship W2898825809A5027339124 @default.
• W2898825809 hasAuthorship W2898825809A5032880409 @default.
• W2898825809 hasAuthorship W2898825809A5046857076 @default.
• W2898825809 hasAuthorship W2898825809A5048352507 @default.
• W2898825809 hasAuthorship W2898825809A5051862250 @default.
• W2898825809 hasConcept C121608353 @default.
• W2898825809 hasConcept C126322002 @default.
• W2898825809 hasConcept C143998085 @default.
• W2898825809 hasConcept C197934379 @default.
• W2898825809 hasConcept C2776256026 @default.
• W2898825809 hasConcept C2778019345 @default.
• W2898825809 hasConcept C2778087573 @default.
• W2898825809 hasConcept C2778570526 @default.
• W2898825809 hasConcept C2778695046 @default.
• W2898825809 hasConcept C2779438470 @default.
• W2898825809 hasConcept C2780333294 @default.
• W2898825809 hasConcept C2780580887 @default.
• W2898825809 hasConcept C71924100 @default.
• W2898825809 hasConceptScore W2898825809C121608353 @default.
• W2898825809 hasConceptScore W2898825809C126322002 @default.
• W2898825809 hasConceptScore W2898825809C143998085 @default.
• W2898825809 hasConceptScore W2898825809C197934379 @default.
• W2898825809 hasConceptScore W2898825809C2776256026 @default.
• W2898825809 hasConceptScore W2898825809C2778019345 @default.
• W2898825809 hasConceptScore W2898825809C2778087573 @default.
• W2898825809 hasConceptScore W2898825809C2778570526 @default.
• W2898825809 hasConceptScore W2898825809C2778695046 @default.
• W2898825809 hasConceptScore W2898825809C2779438470 @default.
• W2898825809 hasConceptScore W2898825809C2780333294 @default.
• W2898825809 hasConceptScore W2898825809C2780580887 @default.
• W2898825809 hasConceptScore W2898825809C71924100 @default.
• W2898825809 hasFunder F4320309856 @default.
• W2898825809 hasIssue "4" @default.
• W2898825809 hasLocation W28988258091 @default.
• W2898825809 hasLocation W28988258092 @default.
• W2898825809 hasOpenAccess W2898825809 @default.
• W2898825809 hasPrimaryLocation W28988258091 @default.
• W2898825809 hasRelatedWork W2003946864 @default.
• W2898825809 hasRelatedWork W2050376166 @default.

• next